Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation
Autore:
Bubalo, Y; Seelig, F; Karbowicz, S; Maziarz, RT;
Indirizzi:
Oregon Hlth Sci Univ, Dept Pharm Serv, Portland, OR 97201 USA Oregon Hlth Sci Univ Portland OR USA 97201 m Serv, Portland, OR 97201 USA
Titolo Testata:
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
fascicolo: 8, volume: 7, anno: 2001,
pagine: 439 - 445
SICI:
1083-8791(2001)7:8<439:ROTODF>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; PREVENTION; EFFICACY; GRANISETRON; ONDANSETRON; EMESIS;
Keywords:
dolasetron; ondansetron; granisetron; hematopoietic stem cell transplantation; bone marrow transplantation; nausea; vomiting; emesis; chemotherapy; total body irradiation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Bubalo, Y Oregon Hlth Sci Univ, Dept Pharm Serv, Mail Code CR9-4,3181 SW Sam JacksonPk Rd, Portland, OR 97201 USA Oregon Hlth Sci Univ Mail Code CR9-4,3181 SW Sam Jackson Pk Rd Portland OR USA 97201
Citazione:
Y. Bubalo et al., "Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation", BIOL BLOOD, 7(8), 2001, pp. 439-445

Abstract

A prospective open-label trial was performed to compare the efficacy of dolasetron with that of ondansetron or granisetron (standard therapy) for prevention of nausea and vomiting associated with high-dose chemotherapy with or without total body irradiation followed by hematopoietic stem cell transplantation (HSCT). In a university teaching hospital setting, 62 patients were randomized to receive either dolasetron 100 mg daily or standard doses of ondansetron or granisetron. In addition to objective data such as numberof episodes of emesis and quantity of rescue antiemetics required, 100 nunvisual analogue scales were used to rate nausea, appetite, and changes in taste. A post-hoc subgroup analysis was performed between groups of patients that were matched for conditioning regimens. Sixty-five percent of the dolasetron-treated patients and 87% of patients in the standard therapy groupachieved a major or complete response (P<.05) based on emetic episodes andnausea score. Patients in the standard therapy group used fewer rescue antiemetics and also rated more favorably on selected questions of the visual analogue scale. No differences in safety parameters or adverse effects werereported. At doses prescribed in this study, dolasetron was less effectivethan granisetron or ondansetron in preventing nausea and vomiting associated with high-dose chemotherapy/total body irradiation followed by HSCT.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 07:42:37